NCT02719613 2026-04-15Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating ElotuzumabBristol-Myers SquibbPhase 2 Completed67 enrolled
NCT03984097 2026-04-09A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)TakedaPhase 1 Completed50 enrolled